India Pharma Outlook Team | Tuesday, 17 March 2026
Sun Pharma has taken a key step forward as the Sun Pharma Ilumya FDA review process moves ahead, with the US Food and Drug Administration accepting its application for expanded use.
The company is seeking approval to extend Ilumya’s indication to treat adults with active psoriatic arthritis, beyond its current use for plaque psoriasis.
The acceptance means the FDA will now evaluate the application in detail, bringing Sun Pharma closer to entering a larger treatment market. The regulatory submission is backed by data from two late-stage clinical trials, which showed that patients receiving Ilumya experienced meaningful improvement in symptoms compared to those on placebo.
Also Read: Advancing Interventional Radiology in India Through Collaboration
Rick Ascroft, CEO of Sun Pharma North America, said: “For many people living with psoriatic disease, joint symptoms often add another layer of burden.” “As we continue to strengthen Sun Pharma’s innovative portfolio, we look forward to working with the FDA throughout the review process.”
Ilumya is already approved in multiple markets for moderate-to-severe plaque psoriasis, a chronic skin condition. With this new filing, Sun Pharma aims to position the drug as a treatment option for psoriatic arthritis, a related disease that affects joints and can lead to long-term damage if untreated.
The Sun Pharma Ilumya FDA review is expected to conclude later this year, with a decision anticipated by the end of October 2026. If approved, the expanded label could significantly increase the drug’s reach, as a notable share of psoriasis patients eventually develop psoriatic arthritis.
This move reflects Sun Pharma’s ongoing focus on strengthening its specialty drug portfolio, particularly in biologics. Expanding Ilumya’s use could boost the company’s global presence and help it compete more effectively in a high-value therapeutic segment.
.jpg)
